Notably, sunitinib, a tyrosine kinase inhibitor achieved promising anti-tumor effects on patients with renal cell carcinoma and artesunate treatment indicated a significant inhibition effect on the sunitinib-resistant renal cell carcinoma cells by inducing ferroptosis through suppressing GPX4 (94). Here, GPX4 is linked to neoplasm.